Dissolved and financials
CVR: 25836812
Previous names: ApS KBIL 17 NR. 1286, STEVIA ApS
DKK -620,833
Gross profit
Net result: DKK -498,287
No owners listed
CVR · view owners
No management registered
CVR · view management
Dissolved
Ceased 16 March 2015
CVR · view overview
1 employee
CVR · 2006
Director role ended: Søren Stenderup
CVR · 29/04/2014
View the full event history
STX PHARMACEUTICALS ApS was a Danish company of the type Anpartsselskab based in København K, founded in 2001. The company has been dissolved on 16 March 2015. The company was registered under the industry Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named STEVIA ApS and ApS KBIL 17 NR. 1286. The company has 1 employee (2006). In 2012, the company reported a gross profit of DKK -620,833 and a net result of DKK -498,287. Equity in the 2012 report amounted to DKK -4,287,693.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 201201/01/2012 – 31/12/2012 | -621 t. | -498 t. | 140 t. | -4.3 mio. | - |
Screen owners and management against the Danish FSA's official PEP lists
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreNo. STX PHARMACEUTICALS ApS is registered in the Danish CVR register with the status Dissolved and ceased on 16 March 2015.
The CVR number of STX PHARMACEUTICALS ApS is 25836812.
In 2012, STX PHARMACEUTICALS ApS reported a gross profit of DKK -620,833.
STX PHARMACEUTICALS ApS had 1 employee in 2006 according to the Danish CVR register.
STX PHARMACEUTICALS ApS was founded on 1 January 2001.
STX PHARMACEUTICALS ApS was registered under the industry Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (industry code 721900).
As of March 16, 2015, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has stepped down as auditor of STX PHARMACEUTICALS ApS.
STX PHARMACEUTICALS ApS was dissolved on March 16, 2015.
As of April 29, 2014, Søren Stenderup has stepped down as adm. dir of STX PHARMACEUTICALS ApS.
On December 23, 2013, the company changed its name from STEVIA ApS to STX PHARMACEUTICALS ApS.
STX PHARMACEUTICALS ApS has published its annual report for 2012. Gross profit came to DKK -620,833, and the net result was DKK -498,287.
As of March 22, 2013, Per Bendix Jeppesen has left the board of directors of STX PHARMACEUTICALS ApS.
As of March 22, 2013, Søren Stenderup has left the board of directors of STX PHARMACEUTICALS ApS.
As of March 22, 2013, Kjeld Hermansen has left the board of directors of STX PHARMACEUTICALS ApS.
As of March 22, 2013, Søren Stenderup is registered as adm. dir of STX PHARMACEUTICALS ApS.
As of March 22, 2013, Per Bendix Jeppesen has stepped down as direktion of STX PHARMACEUTICALS ApS.
As of March 22, 2013, Katrine Steen has stepped down as chairman of STX PHARMACEUTICALS ApS.
As of December 21, 2012, Per Bendix Jeppesen has joined the board of directors of STX PHARMACEUTICALS ApS.
As of December 21, 2012, Per Bendix Jeppesen is registered as direktion of STX PHARMACEUTICALS ApS.
As of December 21, 2012, Katrine Steen is registered as chairman of STX PHARMACEUTICALS ApS.
As of December 21, 2012, Niels Vesth has stepped down as adm. dir of STX PHARMACEUTICALS ApS.
As of November 21, 2012, Ole Bitsch-Jensen has stepped down as chairman of STX PHARMACEUTICALS ApS.
As of November 3, 2008, Ole Bitsch-Jensen is registered as chairman of STX PHARMACEUTICALS ApS.
As of November 3, 2008, Philip Just Larsen has stepped down as chairman of STX PHARMACEUTICALS ApS.
As of May 28, 2008, CHRISTENSEN KJÆRULFF STATSAUTORISERET REVISIONSAKTIESELSKAB has been appointed auditor of STX PHARMACEUTICALS ApS.
As of May 28, 2008, EY Danmark A/S has stepped down as auditor of STX PHARMACEUTICALS ApS.
As of May 28, 2008, Søren Stenderup has joined the board of directors of STX PHARMACEUTICALS ApS.
As of October 19, 2005, EY Danmark A/S has been appointed auditor of STX PHARMACEUTICALS ApS.
As of October 19, 2005, Michael Fræmohs has stepped down as auditor of STX PHARMACEUTICALS ApS.
As of May 17, 2005, Per Bendix Jeppesen has left the board of directors of STX PHARMACEUTICALS ApS.
As of May 17, 2005, Søren Gregersen has left the board of directors of STX PHARMACEUTICALS ApS.
As of May 17, 2005, Philip Just Larsen is registered as chairman of STX PHARMACEUTICALS ApS.
As of May 17, 2005, Niels Vesth is registered as adm. dir of STX PHARMACEUTICALS ApS.
As of May 17, 2005, Kjeld Hermansen has stepped down as direktion of STX PHARMACEUTICALS ApS.
As of June 18, 2001, Michael Fræmohs has been appointed auditor of STX PHARMACEUTICALS ApS.
As of June 18, 2001, JUT NR. 2180 A/S has stepped down as auditor of STX PHARMACEUTICALS ApS.
As of June 18, 2001, Per Bendix Jeppesen has joined the board of directors of STX PHARMACEUTICALS ApS.
As of June 18, 2001, Søren Gregersen has joined the board of directors of STX PHARMACEUTICALS ApS.
As of June 18, 2001, Kjeld Hermansen has joined the board of directors of STX PHARMACEUTICALS ApS.
As of June 18, 2001, Peter Andreas Stakemann has left the board of directors of STX PHARMACEUTICALS ApS.
As of June 18, 2001, Kjeld Hermansen is registered as direktion of STX PHARMACEUTICALS ApS.
As of June 18, 2001, Kim Madsen has stepped down as direktion of STX PHARMACEUTICALS ApS.
On June 18, 2001, the company changed its name from ApS KBIL 17 NR. 1286 to STEVIA ApS.
As of January 1, 2001, JUT NR. 2180 A/S has been appointed auditor of STX PHARMACEUTICALS ApS.
As of January 1, 2001, Peter Andreas Stakemann has joined the board of directors of STX PHARMACEUTICALS ApS.
As of January 1, 2001, Kim Madsen is registered as direktion of STX PHARMACEUTICALS ApS.
STX PHARMACEUTICALS ApS was founded on January 1, 2001.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
